Scientific context only. Not medical advice, not a recommendation to use.
At a glance
Leuprorelin (also leuprolide) is a synthetic nonapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH). It is an approved prescription medicine in several jurisdictions, including for advanced prostate cancer, endometriosis, uterine fibroids and central precocious puberty. This page neutrally summarizes the evidence base and legal status and is not a usage or dosing recommendation.
Researched for
Advanced prostate cancer (androgen-deprivation effect)Endometriosis-associated symptomsUterine fibroidsCentral precocious puberty
Official status
US: Prescription
In the US, approved by the FDA as a prescription medicine (e.g., Lupron, Eligard) for indications including advanced prostate cancer, endometriosis, uterine fibroids and central precocious puberty.
Leuprorelin is a GnRH-receptoragonist. After binding to pituitary GnRH receptors, it first causes a transient surge in luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release — the so-called flare. With continuous, non-pulsatile exposure the receptors are downregulated and desensitized, suppressing gonadotropin secretion and consequently lowering sex steroids (testosterone or estradiol) to low levels. This mechanism underlies the literature-described use in hormone-dependent conditions.
02
Evidence at a glance
Reading note. The distribution shows on which evidence tier each observation sits. Strong colours mark stronger evidence — weaker tiers are deliberately visible, not hidden.
4 observations · 2 tiers
Human RCT
3
Human trial
1
03
What the studies show
Human RCT
Mensch
Crawford ED et al. 1989
With continuous exposure, LH and FSH are suppressed, with subsequent lowering of sex steroids.
What does NOT follow: Suppression follows an initial transient stimulation (flare). Findings derive from controlled studies in defined clinical indications and do not transfer to other contexts.
Human RCT
Mensch
Dlugi AM et al. 1990
In randomized endometriosis studies, leuprorelin was associated with greater reduction of pain parameters versus placebo.
What does NOT follow: Efficacy was studied in specific patient populations over limited periods; hormonal suppression carries its own risks (see adverse events).
Human RCT
Mensch
Crawford ED et al. 1989
In advanced prostate cancer, leuprorelin lowers testosterone to castrate range; combined with an antiandrogen, one large trial reported a survival advantage over leuprorelin alone.
What does NOT follow: The reported advantage concerns combination treatment in a defined stage; later studies and meta-analyses have nuanced the picture of combined androgen blockade.
Human trial
Mensch
Lee PA et al. 2012
In central precocious puberty, 3-month depot formulations suppressed the stimulated LH response in a high proportion of treated children.
What does NOT follow: Result from an open-label phase III study in a pediatric population; suppression rates differed between the formulations studied.
04
Where studies disagree
Open question
Is there a distinct 'post-GnRH-agonist syndrome' with persistent complaints after stopping therapy?
POSITION A
Patient groups report persistent bone, joint and cognitive/mood complaints beyond the end of therapy.
POSITION B
Without a control group such symptoms are hard to separate from underlying disease, age and concurrent therapy; a distinct syndrome is not established.
CURRENT STATE · Bone-density loss under GnRH agonists is documented; a defined long-term syndrome beyond that remains contested and understudied.
05
Pharmacokinetics
Theoretical concentration curve at a half-life of 3 h. Pure pharmacokinetic model — not a dosing recommendation.
Which routes of administration the available studies describe — neutral reporting, not a usage guide.
Subcutaneous
The pharmacokinetic and clinical literature describes subcutaneous administration, including sustained-release depot formulations. Purely descriptive, not a usage instruction.
Intramuscular
Intramuscular depot formulations are described in registration studies for several indications. Purely descriptive, not a usage instruction.
06d
Safer use & risks
Risk notes for harm reduction — descriptive, not a usage or dosing guide.
⚠ Important — please read
This platform does NOT provide usage or dosing instructions. The points below describe risks and are meant to help avoid harm — they do not replace medical advice. Anyone who uses a substance should discuss it with a doctor.
This substance is approved (in at least one country) — use belongs in medical hands, within the approved indication and a physician-set dose.
Online numbers are not a benchmark
Amounts from TikTok, YouTube and forums are mostly imitation rather than data — and are often wrongly derived from animal studies (µg/kg). Not a reliable benchmark for humans.
Sterility & infection risk
Injection solutions prepared or stored non-sterile carry an infection and abscess risk. Contamination is common with grey-market product.
Unknown product quality
Research-/grey-market product is not quality-tested: identity, purity and actual content are often unknown, and counterfeits occur.
Mind interactions
Combinations with medications or pre-existing conditions can carry risks (see the Interactions section). Clarify with a doctor beforehand.
Warning signs — seek medical help
With persistent pain, redness/swelling at the injection site, fever, shortness of breath, racing heart, chest pain or allergic reactions, seek medical help immediately.
A doctor, not a forum
Concrete questions about use and amount belong in a conversation with a doctor — not in a comment thread.
07
Known adverse events from studies
Factual reporting of what studies observed. Not a safety statement for individual use.
Human RCT
Consequences of hormonal suppression such as hot flushes; with prolonged use, a decrease in bone mineral density has been described.
Frequency and severity depend on indication, duration and population; findings derive from controlled studies in approved indications.
Human trial
Initial transient symptom worsening (flare) at treatment onset due to the early rise in gonadotropins and sex steroids.
In clinical indications this is medically managed; the description is a neutral account of the mechanism, not a usage instruction.
Human trial
Injection-site reactions have been reported in studies of depot formulations.
Reported in controlled studies; not a complete safety assessment and no substitute for the official prescribing information.
07b
Interactions & combinations
Documented interactions and contraindications from studies, prescribing information and guidelines. Where no data exists, this is stated.
Reporting of risks, NOT a combination guide. The absence of an entry does not mean „safe to combine“ but „not sufficiently studied“.
No documented interactions recorded
We have not yet found robustly documented interactions for this peptide. This does NOT mean none exist — the data is limited.
10
Anecdotal observations
Weakest evidence tier — not supported by studies
Reading note. This section gathers popular claims from communities and forums. They are explicitly marked as weakest-tier evidence. Unblinded self-reports are particularly prone to placebo, recall and confirmation biases.
Why no amounts or protocols are listed here. We deliberately show only WHAT communities report — not in what amount or how it is used. Anecdotal "doses" or "biohacker protocols" are neither verified nor standardised nor safe; publishing them would be a usage guide, which we do not provide on principle. Specific amounts belong in a conversation with a doctor, not in a forum.
There is an active patient discussion about persistent complaints after therapy (bone, joints, mood), partly described as long-term sequelae.
recurring, with an organised critical voice
Not supported by studies: Self-reported long-term sequelae are hard to separate from underlying disease, age and concurrent therapy without a control group. Bone-density loss under GnRH agonists is, however, documented.
10b
What online communities discuss
Recurring themes from Reddit, Quora and patient forums — synthetically summarised, sources linked. Not scientific evidence, but a signal of what users report. Deliberately separated from the study base.
Non-scientific sources. What users report in forums — synthetically summarised, paraphrased, with link to source. Not validated by studies.
Sorted by discussion frequency · 1 Thema
Discussion frequency: ~320 aggregated reviews across two formulations
On drugs.com, patient ratings for leuprolide are mixed to critical: Lupron Depot 6.0 out of 10 (~252 reviews), Lupron 5.8 (~74). Recurring mentions are hot flashes, weight gain, fatigue, bone and joint pain and mood changes — consequences of the strong hormone suppression. There is a visible group of highly critical long-term reports.
What this does NOT mean:Review platforms are self-selected, unblinded and not representative; the figures are a snapshot (as of June 2026). They do not replace controlled data — see the studies section. Leuprolide is used across very different indications (prostate cancer, endometriosis, precocious puberty) — reports mix very different situations.
In the US, approved by the FDA as a prescription medicine (e.g., Lupron, Eligard) for indications including advanced prostate cancer, endometriosis, uterine fibroids and central precocious puberty.
2026-06-07
Germany
Prescription
In Germany, available as a prescription medicine (e.g., Enantone, Eligard, Trenantone); dispensed by pharmacies on a physician's prescription only.
2026-06-07
12
Reconstitution calculator
Pure mg/mL maths — works like a calculator. Not a usage recommendation.
Peptides ship as a dry powder. Once dissolved in a liquid (reconstitution), this calculator answers a single question: how much substance is in one millilitre of solution afterwards?
1Enter the vial's substance amount (printed on the label).
2Enter how much solvent you add.
3Result = concentration in mg per mL.
Printed on the label
/
Liquid you add
=
2.50
mg / mL
5 mg in 2 mL gives 2.50 mg/mL — each millilitre contains 2.50 mg of substance.